Josh Shapiro’s administration, convinced GSK to choose Marietta over other sites for a new 270,000 square-foot building, expected to be completed in two to three years, that will house ...

For GSK’s Ramakrishnan, who has served as CDTO since 2021, the biggest challenge was helping her company get a head start in ...

The drug is a needed new option for treating uncomplicated UTIs, a common infection that’s becoming harder to treat as rates ...

As an incentive, Fairfield approved a community reinvestment area agreement with both companies. It provides a 5-year, 45 ...

In addition to established platform technologies, GSK is building new platforms such as the Multiple Antigen-Presenting System (MAPS) and mRNA, key to addressing the most complex diseases.

The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in ...

The new programme will leverage Oxford's expertise ... “By exploring precancer biology and building on GSK’s expertise in the science of the immune system, we aim to generate key insights ...

Ramakrishnan used the example of GSK’s work against chronic hepatitis B, with new data capabilities helping ... and whether you’re building talent and capabilities. “This means that we ...